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Abstract: 
 
Dietary supplements are a multi-billion dollar business, with yearly profit increases. Allegedly 
safe, these supplements are marketed to a variety of niches, encompassing claims from immune 
support to weight loss. Six sports nutrition supplements were acquired that were labeled to 
contain the furanocoumarin(s) bergamottin and/or 6′,7′-dihydroxybergamottin (DHB), both of 
which are potent irreversible inhibitors of the prominent drug metabolizing enzyme cytochrome 
P450 3A (CYP3A). Both furanocoumarins are typically present in grapefruit juice, which has 
been shown to inhibit intestinal CYP3A, perpetrating an increase in the systemic exposure of 
certain concomitant ‘victim’ drugs. The acquired supplements were analyzed using ultra-
performance liquid chromatography coupled to both a photodiode array (PDA) detector and a 
triple quadrupole mass spectrometer (MS). Contrary to the product labeling, four of the 
supplements contained no detectable quantities of either furanocoumarin (LOD 0.060 
μg/capsule), while two of the supplements contained minimal amounts (one contained 12.13 
(±0.23) μg bergamottin and 65.51 (±0.64) μg DHB per capsule; the other contained 2.705 
(±0.069) μg bergamottin per capsule and no detectable quantities of DHB). A CYP3A inhibition 
bioassay was used to assess whether the actual content of the furanocoumarins correlated with 
CYP3A inhibitory activity. Despite the low amounts of bergamottin and DHB, CYP3A 
inhibition by the supplements was greater than could be accounted for by the two 
furanocoumarins. The additional activity suggests the presence of other potent or highly 
abundant CYP3A inhibitors. 
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Article: 
 
1. Introduction 
 
Dietary supplements are a thriving industry in the United States, surpassing $30 billion in sales 
in 2011 [1] and encompassing various facets of the market. They can include single- or multi-
vitamins, minerals, herbs and botanicals [2], weight-loss aids, and sports nutrition products. Of 
these, sports nutrition supplements represented 12% of the total sales [1], [3]. Some of these 
supplements are labeled to contain bergamottin and/or 6′,7′-dihydroxybergamottin (DHB) (Fig. 
1), two furanocoumarins found in grapefruit juice that have been shown to interfere with 
cytochrome P450 3A (CYP3A) in the intestine through irreversible inhibition of the 
enzyme [4], [5], [6], [7]. 
 
 
Fig. 1. Bergamottin (1) and 6′, 7′-dihydroxybergamottin (DHB; 2). 
 
Intestinal CYP3A contributes significantly to the pre-systemic (‘first-pass’) metabolism of 
numerous orally administered drugs, including felodipine, lovastatin, and 
cyclosporine [6], [7], [8], [9]. Inhibition of intestinal CYP3A by furanocoumarins in grapefruit 
juice can increase the systemic exposure of these ‘victim’ drugs to an extent that leads to side 
effects ranging from relatively mild (e.g., hypotension and dizziness with some calcium channel 
blockers) to potentially severe (e.g., nephrotoxicity with some immunosuppressants). CYP3A 
also is involved in the oxidative metabolism of both endogenous and exogenous androgens, 
including testosterone [10] and synthetic steroids marketed as body building supplements. For 
example, two synthetic steroids in the supplements Finaflex 1-Andro and Finaflex 1-Alpha 
include 3-hydroxy-5α-androst-1-ene-17-one and 3-enanthoxy-5α-androst-1-ene-17-one, 
respectively. These additives are sold as mixtures labeled to contain bergamottin and/or DHB, 
allegedly enhancing the effect of the steroids by “mak[ing] the active ingredient more bio-
available” (Finaflex 1-Andro). At least one supplement, SciFit DHB 300, was labeled to contain 
300 mg of pure DHB in each capsule and was presumably intended to be taken concomitantly 
with other products of the consumer's choice. Grapefruit juice contains between 2.5 and 36.3 μM 
bergamottin and 0.2 and 89.0 μM DHB [11], [12], [13], equating to between 0.2 to 2.9 mg 
bergamottin and 0.02 to 7.4 mg DHB per 8-oz (240-mL) serving. Grapefruit juice containing 
2.2 mg bergamottin and 2.7 mg DHB per 240-mL serving doubled median area under the curve 
of felodipine relative to control [6]. Supplements containing bergamottin or DHB at similar 
amounts may pose a risk for consumers taking concomitant medications that undergo extensive 
CYP3A-mediated intestinal metabolism [6], [7], [8], [9]. 
 
Other dietary supplements have been shown to modulate drug metabolism with subsequent 
unwanted effects, most notably Hypericum perforatum L. (St. John's wort). Opposite to 
grapefruit juice, St. John's wort induces the expression [14] of intestinal (and hepatic) CYP3A, as 
well as P-glycoprotein (P-gp), an apically located transmembrane efflux protein that transports 
susceptible substrates back into the intestinal lumen or into bile [15]. Induction of CYP3A and P-
gp can decrease significantly the systemic exposure and efficacy of diverse drugs, including oral 
contraceptives, cyclosporine, and methadone [16], [17], [18], [19]. The risk of dietary 
supplement–drug interactions is exacerbated by both the lack of pre- and post-launch scrutiny of 
supplements [2], [20], as well as chronic underreporting of supplement use by 
patients [21], [22], [23], [24]. 
 
To address the possibility of dietary substance–drug interactions perpetrated by supplements 
containing bergamottin and/or DHB, both quantitative analysis and a CYP3A inhibitory activity 
bioassay were employed. The quantification method utilized ultra-performance liquid 
chromatography (UPLC) for rapid (3.0 min) separation of the supplement extracts, coupled to 
both a photodiode array (PDA) detector and a triple quadrupole mass spectrometer (MS) for 
quantification. Based on a previously published study [13], this method was refined for rapid 
analysis and made use of the MS to identify more easily the analyte peaks in the complex 
extracts. The quantification method was used to evaluate the labeled vs. actual content of 
bergamottin and DHB in selected supplements. The bioassay was used to assess whether the 
actual content of the furanocoumarins correlated with CYP3A inhibitory activity. 
 
2. Materials and methods 
 
2.1. Materials and chemicals 
 
Bergamottin was purchased from ChromaDex (Irvine, CA; purity ≥96.9%) and Sigma–Aldrich 
(St. Louis, MO; purity ≥98.0); DHB was purchased from Cayman Chemical (Ann Arbor, MI; 
purity ≥98.0%) and Sigma–Aldrich (purity ≥97.2%). Midazolam (purity ≥ 99.9%), 1′-
hydroxymidazolam (purity ≥98.0%), ketoconazole (purity ≥ 98.0%), alprazolam (purity 
≥99.0%), and NADPH were purchased from Sigma–Aldrich. Purity of standards is reported as 
determined by HPLC (TLC in the case of alprazolam) by the manufacturers. A not-from-
concentrate grapefruit juice (Simply Grapefruit, Simply Orange Juice Co., Apopka FL; lot 
AMC3 E 01:13) was purchased from a local grocery store. Methanol (MeOH) was purchased 
from Pharmco-Aaper (Shelbyville, KY) and Fischer Scientific (Waltham, MA). UPLC-grade 
water (H2O) and acetonitrile (CH3CN) were purchased from Fisher Scientific. Pooled human 
intestinal microsomes (HIM) (n = 18 donors) were purchased from Xenotech (Lenexa, KS). 
 
2.2. Supplements analyzed 
 
Six supplements labeled to contain bergamottin and/or DHB were selected: SciFit DHB 300 
(SciFit, Oakmont, PA; lot 57454), Trisorbagen (Anabolic Xtreme, Tempe, AZ; lot 202609), 
Xceler8 DHB (VitaSport, Chino Hills CA; lot US 37700), AttentionLink (Hi-Tech 
Pharmaceuticals, Inc., Norcross GA; lot 08132039), Finaflex 1-Alpha (Redefine Nutrition, 
Alpharetta GA; lot 824912013), and Finaflex 1-Andro (Redefine Nutrition, Alpharetta GA; lot 
0500313). Five capsules from each product were analyzed quantitatively. With the exception of 
AttentionLink, all capsules were opened and their contents weighed. Because the AttentionLink 
capsules contained a viscous material encased in a microcrystalline cellulose outer layer, they 
were weighed in their entirety (Supplementary Information, Table S1). 
 
2.3. Extraction of supplements and grapefruit juice 
 
The contents of the capsules (and in the case of AttentionLink, the entire capsule) were shaken 
for 5 h at 100 rpm in 3.0 mL of MeOH. Aliquots (600 mL) of the extract were filtered using 
1.7 mL polypropylene Spin-X centrifuge tube filters (0.22 μm; Corning, Tewskbury, MA) and 
centrifuged for 10 min at 14 × 103 rpm. This method was modified from a study measuring 
furanocoumarins in teas, fruits and vegetables that reported MeOH to be the most efficient 
solvent [25]. Grapefruit juice was extracted as described previously [13] by shaking 240-mL 
aliquots of juice with three consecutive washes of ethyl acetate (EtOAc). 
 
2.4. Preparation of standards 
 
Bergamottin and DHB were dissolved in MeOH to create stock solutions of 1.6 mM each. Two 
calibration curves containing both standards were prepared from these stock solutions. One 
standard curve (PDA curve) used six concentrations ranging from 5.00 μM to 160.0 μM for both 
bergamottin and DHB; the second standard curve (MS curve) used five concentrations ranging 
from 0.313 μM to 5.00 μM for both bergamottin and DHB. 
 
2.5. UPLC-PDA-MS analysis 
 
UPLC separations of the standards solutions, supplement extracts, and grapefruit juice extract 
were performed using a Waters Acquity UPLC system (Milford, MA) equipped with an 
autosampler, PDA detector, column manager, and binary solvent manager. An HSS C18 column 
(50 mm × 2.1 mm i.d., 1.8 μm, Waters, Milford, MA) was used for all chromatographic 
separations, held at a constant temperature of 40 °C. The gradient system consisted of 0.1% 
formic acid in CH3CN (A) and 0.1% formic acid in H2O (B) at a flow rate of 0.6 mL/min. The 
gradient used 30–60% A at 0–1.2 min, 60–100% A at 1.2–2.0 min, and 100% A at 2.0–3.0 min. 
Both standards and samples were injected in triplicate, at a volume of 2.0 μL. 
 
The UPLC system was coupled to a Thermo Scientific TSQ Quantum Access triple quadrupole 
mass spectrometer (Waltham MA) with a heated electrospray ionization (HESI) source. Analyses 
were conducted in positive mode, with spray voltage 3800 V, vaporizer and capillary 
temperatures 300 °C and 350 °C, respectively, and sheath gas and auxiliary gas 45 and 35 
(arbitrary units), respectively. Tube lens offset and skimmer offset were 89 and 0, respectively. 
The mass spectrometer was calibrated externally using polytyrosine. Data were collected from 
the mass spectrometer using full scan mode, using a scan time of 0.3 s, and mass range 150–
500 m/z; data were collected at 250 nm on the PDA. All data were analyzed using Xcalibur V2.2 
software. 
 
2.6. Method validation 
 
Linearity of the calibration curves was assessed by least-squares analysis. Precision and accuracy 
were determined by calculating the relative standard deviation (RSD) and relative error (RE), 
defined as the percent difference between the mean observed concentration and the nominal 
concentration of three replicate analyses of the standards. All analyses of the extracts were 
performed in triplicate on a single day. Interday RSD and RE were determined by analyzing the 
standard solutions in triplicate on three separate days. The limit of detection (LOD) and limit of 
quantification (LOQ) were defined as 3.3 s/m and 10 s/m, respectively (where s is the standard 
deviation of the response and m is the slope of the calibration curve), as per the guidelines set 
forth by the International Conference on Harmonisation (ICH) [26]. 
 
Matrix effect was evaluated by comparing the relative responses of analyte spiked into a MeOH 
blank and the supplement extracts [27]. A 2.5-μL aliquot of a 20 mM bergamottin and DHB 
solution was added to 497.5 μL of MeOH and supplement extract; a 2.5-μL aliquot of MeOH 
was added to 497.5 μL of the same supplement extracts to provide a comparison to the non-
spiked supplements. The analyte peak areas of the spiked supplements (S) minus the peak areas 
of the non-spiked supplements (U) were compared to the average peak area of the spiked MeOH 
(M) and expressed as a percent recovery: (S − U)/M*100. Extraction efficiency was evaluated by 
adding 30 μg of bergamottin and DHB to four capsules of each supplement. The supplements 
were extracted as described in Section 2.3, and quantification was performed as described in 
Section 2.5. The average amount measured in non-spiked capsules was subtracted from the 
amount measured in spiked capsules, and the remainder was used to calculate percent recovery. 
 
2.7. CYP3A inhibition assay 
 
A 500-μL aliquot of each supplement extract, and a 50-μL aliquot of grapefruit juice extract 
were dried under air. A reconstitution and dilution scheme was devised using the product with 
the highest measured amount of DHB (SciFit DHB 300). The dried extract of SciFit DHB 300 
was reconstituted with MeOH (130 μL), which was diluted 1:10 in MeOH. Each of these 
methanolic solutions was diluted further into incubation mixtures (see below) to yield final DHB 
concentrations of 1 and 0.1 μM; the higher concentration approximates the Ki of DHB toward 
CYP3A using HIM and midazolam as the probe substrate [10]. The remaining dried supplement 
extracts were reconstituted and diluted in the same manner as SciFit DHB 300. The dried 
grapefruit juice extract was reconstituted with MeOH (50 μL), then diluted 1:10 in MeOH to 
yield final DHB concentrations of 1 and 0.1 μM in the incubation mixtures. 
 
Incubation mixtures, prepared in 96-well plates, consisted of midazolam (4 μM), HIM 
(0.05 mg/mL protein), inhibitor (diluted extract, bergamottin, DHB, ketoconazole) or vehicle 
control, and potassium phosphate buffer (100 mM, pH 7.4). The final concentrations of pure 
bergamottin and DHB and ketoconazole were 1 and 0.1 μM; the final concentration of MeOH 
(v/v) was 1.0%. After equilibrating the mixtures for 5 min at 37 °C, reactions were initiated with 
nicotinamide adenine dinucleotide phosphate (1 mM final concentration), yielding a final volume 
of 200 μL. Reactions were terminated after 4 min by removing a 100-μL aliquot and adding to 
300 μL of ice-cold CH3CN containing internal standard (300 μg/mL alprazolam). Samples were 
vortexed (∼30 s) and centrifuged (3000 g × 10 min at 4 °C), after which 100 μL of supernatant 
were removed and analyzed for 1′-hydroxymidazolam by LC-MS-MS on an API 6500 QTrap 
operated in MRM mode and equipped with an electrospray ionization source. Calibration 
standards were matrix-matched and were linear from 3.9 to 2000 nM. The QTrap was coupled to 
a Shimadzu Nextera UHPLC system (Kyoto, Japan). Chromatographic separation of midazolam, 
1′-hydroxymidazolam, and alprazolam was achieved with a Thermo Scientific Aquasil 
C18(2.1 × 50 mm, 3 μm) HPLC column (Waltham, MA) using a gradient method following a 7-
μL injection of each supernatant. The gradient system consisted of 0.1% formic acid in CH3CN 
(A) and 0.1% formic acid in H2O (B), at a flow rate of 0.75 mL/min. The gradient used 5% A at 
0–0.4 min, 5–95% A at 0.4–1.5 min, 95% A at 1.5–2.1 min, 95–5% A at 2.1–2.11 min, and 5% 
A at 2.11–3.0 min. Sample and column temperatures were 4 °C and 40 °C, respectively. Quality 
controls (QCs) of 10, 100, and 1500 nM were used to assess accuracy. All standards and QCs 
were accurate to within 20% of the nominal value; QC precision was <15% RE. 
 
3. Results and discussion 
 
3.1. Method validation 
 
The PDA calibration curve (5.00 μM to 160.0 μM) showed excellent linearity in UV response 
(bergamottin R2 = 0.9995, DHB R2 = 0.9996); however, the MS response exhibited a limited 
linear dynamic range (0.156–5.00 μM). Because of the latter, the UV detection was used to 
analyze supplements with analytes corresponding to the higher concentration range. The second 
curve (0.156–5.00 μM) was linear in both the UV (bergamottin R2 = 0.9966, DHB R2 = 0.9993) 
and MS (bergamottin R2 = 0.9968, DHB R2 = 0.9977) response; due to the superior resolving 
power of MS, afforded by the ability to select for specific m/z, the MS signals were used to 
quantify supplements with analyte concentrations in this range. The LODs were 0.10 
(bergamottin) and 0.073 μM (DHB) for the PDA curve and 0.054 μM (bergamottin and DHB) 
for the MS curve. The LOQs were 1.8 μM (bergamottin) and 0.22 μM (DHB) for the PDA curve 
and 0.16 μM (bergamottin and DHB) for the MS curve. Parameters for the standard curves are 
summarized in Table 1. When converted to μg/capsule, the LODs were 0.12 μg (bergamottin) 
and 0.074 μg (DHB) for the PDA curve and 0.060 μg (bergamottin and DHB) for the MS curve, 
while the LOQs were 2.0 μg (bergamottin) and 0.22 μg (DHB) for the PDA curve and 0.18 μg 
(bergamottin and DHB) for the MS curve. 
 
Table 1. Parameters of calibration curves. 
 Analyte Retention time, min (± SD) Slope (±SD) r2 LOD (μM) LOQ (μM) 
PDA curve Bergamottin (1) 2.21 (±0.01) 4.087 × 103 (±24) 0.9995 0.10 1.8 
(5.00–160.0 μM) DHB (2) 1.24 (±0.01) 2.451 × 103 (±9) 0.9996 0.073 0.22 
MS curve Bergamottin (1) 2.29 (±0.01) 2.101 × 106(±2.7 × 104) 0.9968 0.054 0.16 
(0.313–5.00 μM) DHB (2) 1.30 (±0.01) 2.729 × 106(±4.5 × 104) 0.9977 0.054 0.16 
 
Table 2. Intraday and interday precision and accuracy of the PDA calibration curve. 
Analytes Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
Bergamottin (1) 
160 0.52 5.8 3.0 4.3 
80.0 0.40 3.8 2.3 1.1 
40.0 0.58 0.69 2.3 2.1 
20.0 0.47 1.9 1.9 4.0 
10.0 0.20 3.7 3.8 1.7 
5.00 3.6 1.2 3.7 2.5 
DHB (2) 
160 0.47 0.64 0.44 0.81 
80.0 0.37 1.3 1.2 2.1 
40.0 0.32 3.8 5.3 3.1 
20.0 1.9 4.8 4.4 3.7 
10.0 8.0 3.4 5.9 0.65 
5.00 0.45 1.0 1.4 1.9 
 
Intraday precision in the PDA curve was below 1.0% for both analytes (Table 2) except at one 
concentration (10 μM), which had an RSD of 8.0%. Interday precision for the same standard 
curve ranged from 1.2 to 5.9%. The RE for both analytes, both intra and interday, was below 
5.8%. The measurements from the MS curve (Table 3) had slightly higher RSDs (ranging from 
1.2 to 5.4% intraday and 1.4 to 7.0% interday); whether this decrease in precision was inherent to 
the MS detector or a consequence of the lower concentrations in the standard curve is unknown. 
The RE for both analytes was, in general, below 5.4%, with a maximum RE of 8.0% for 
bergamottin and 6.7% for DHB. 
 
Table 3. Intraday and interday precision and accuracy of the MS calibration curve. 
Analyte Concentration of standard solution injected (μM) Intraday Interday 
  RSD (%) RE (%) RSD (%) RE (%) 
Bergamottin (1) 
5.00 4.4 1.2 4.3 2.8 
2.50 3.0 2.4 3.7 2.2 
1.25 4.6 5.2 4.5 5.4 
0.625 4.9 8.0 7.0 2.7 
0.313 5.4 3.2 5.4 0.35 
DHB (2) 
5.00 1.7 1.6 1.4 1.3 
2.50 1.2 4.6 2.1 3.8 
1.25 1.8 6.7 3.4 4.3 
0.625 4.6 1.6 3.8 4.3 
0.313 2.7 2.9 4.9 3.1 
 
Except for Xceler8 DHB, matrix effects (expressed as percent recovery) were within 15% (Table 
4). Because of the substantial matrix effect of Xceler8 DHB, further analysis of this supplement, 
including quantification and in vitro testing, is not reported. Extraction efficiency was above 
84.8% (±1.1) for all supplements tested except for AttentionLink, which demonstrated 77.7% 
(±3.7) recovery of bergamottin (Table 5). 
 
Table 4. Matrix effects expressed as mean recoveries of spiked analyte in supplement extracts. 
 % Recovery (± SD) 
 Bergamottin (1) DHB (2) 
SciFit DHB 300 97.1 (±4.9) 102.2 (±9.2) 
Trisorbagen 100.2 (±4.9) 99.3 (±8.1) 
Xceler8 DHB 9.2 (±1.9) 9.54 (±0.80) 
AttentionLink 85.9 (±6.7) 102.0 (±3.0) 
Finaflex 1-Alpha 100.5 (±1.9) 104.1 (±5.3) 
Finaflex 1-Andro 88.2 (±5.9) 87.5 (±5.4) 
 
Table 5. Extraction efficiency expressed as mean recoveries of spiked analyte in supplement 
extracts. 
 % Recovery (±SD) 
 Bergamottin DHB 
SciFit DHB 300a 101. (±12) 100.1 (±7.0) 
Trisorbagen 90.4 (±1.1) 84.8 (±1.1) 
AttentionLink 77.2 (±3.7) 99.7 (±4.3) 
Finaflex 1-Alpha 93.49 (±0.80) 98.0 (±3.2) 
Finaflex 1-Andro 98.6 (±5.1) 86.7 (±3.1) 
Xceler8 DHB is not included in this table due to significant matrix effects (Table 4). 
aThe percent recovery for SciFit DHB 300 was calculated as the amount measured in a spiked capsule minus the 
average amount of analyte measured in non-spiked capsules (12.13 (±0.23) μg bergamottin and 65.51 (±0.64) μg 
DHB). 
 
3.2. Quantification of bergamottin and DHB in dietary supplements and grapefruit Juice 
 
Of the six supplements analyzed, only two had detectable amounts of bergamottin and DHB 
(Table S2, Supplementary Information). The SciFit DHB 300 capsules, the label for which 
claimed 300 mg pure DHB, contained an average of 12.13 (±0.23) μg bergamottin and 65.51 
(±0.64) μg DHB per capsule. Bergamottin was detected in Xceler8 DHB, but due to substantial 
matrix effects (Section 3.1, Table 4), quantification is not reported. Complete per-capsule data 
are available in Supplementary Information, Table S1. In contrast to the supplements, both 
bergamottin and DHB were detected readily in grapefruit juice; concentrations were 4.485 
(±0.031) and 8.327 (±0.047) μM, respectively (0.449 and 0.743 mg per 240-mL serving). 
 
 
Fig. 2. Comparison of the effects of supplements labeled to contain 6′,7′-dihydroxybergamottin 
(DHB) with known CYP3A inhibitors on CYP3A activity in human intestinal microsomes. Pure 
DHB and bergamottin, as well as the known CYP3A inhibitor ketoconazole, were tested at 
0.1 μM (open bars) or 1 μM (solid bars). The methanolic extract of SciFit was tested such that 
the final concentration of DHB was 0.1 or 1 μM. All other supplement extracts were tested at the 
same dilutions as SciFit (10× and 1×; open bars and closed bars, respectively). The grapefruit 
juice extract (GFJ) was tested such that the final concentration of DHB was 0.1 or 1 μM. The 
concentrations of DHB in the incubations containing SciFit, GFJ, and purified DHB were the 
same (0.1 and 1 μM; open and filled orange bars, respectively). Bars and error bars denote the 
means and SDs, respectively, of triplicate incubations. Inhibition by ketoconazole at 1 μM was 
below the limit of quantification (BLQ). *p < 0.05 versus the 1× dilution; #p < 0.05 versus pure 
DHB at 0.1 μM; †p < 0.05 versus pure DHB at 1 μM. Statistical comparisons were made via two-
way ANOVA with a Bonferroni adjustment. 
 
3.3. CYP3A inhibition assay 
 
Vehicle control reaction velocities of 416 ± 29 pmol/min/mg protein demonstrated acceptable 
CYP3A activity in the HIM lot. The CYP3A inhibitor, ketoconazole, abolished 1′-
hydroxymidazolam formation at 1 μM and inhibited activity by ∼80% at 0.1 μM (Fig. 2). 
Bergamottin showed no inhibition at the concentrations tested. This lack of effect by bergamottin 
was expected at these concentrations based on an apparent Ki > 10 μM with HIM [10]. DHB at 
0.1 and 1 μM inhibited activity by 5 and 42%, respectively. Except for bergamottin, 
concentration dependency was observed for each treatment (p < 0.05; 2-way ANOVA with 
Bonferroni adjustment). Because the extract dilutions were based on the measured DHB content 
in the SciFit DHB 300 supplement, this supplement was expected to behave most like authentic 
DHB. However, this supplement was considerably more potent than DHB (Fig. 2). The CYP3A 
inhibitory activity of SciFit was similar to that of the grapefruit juice extract, which, like SciFit, 
was diluted such that the final concentrations of DHB were 0.1 and 1 μM. In addition to SciFit, 
two supplements (Trisorbagen and AttentionLink) demonstrated potent inhibition of CYP3A 
activity despite the fact that neither bergamottin nor DHB were detected. Finaflex 1-Alpha 
appeared to stimulate CYP3A activity at the lower concentration, which has been observed with 
low concentrations of bergamottin (<2.5 μM) in incubations with HIM and midazolam [28]. 
 
4. Conclusions 
 
All of the supplements analyzed were labeled to contain bergamottin and/or DHB, but only one 
contained detectable quantities of these analytes, and, even then, in much lower amounts than the 
label claimed. While these results reflected poorly on label accuracy, the low quantities were 
initially reassuring in consideration of possible supplement–drug interactions, particularly when 
one product was labeled to contain 300 mg DHB per capsule. The quantity of DHB measured in 
one SciFit capsule (0.065 mg) was considerably less than that measured in a glass (240 mL) of 
grapefruit juice (0.6–3.8 mg) used in clinical studies reporting a significant increase in victim 
drug systemic exposure when co-administered with the juice [6], [29], [30], [31], [32]. A 
consumer would have to take at least 10 capsules of SciFit to achieve a dose of DHB equivalent 
to lowest amount of DHB in a glass of grapefruit juice reported to cause a clinical 
interaction [32]. Despite the expectation that the supplements would lack CYP3A inhibitory 
activity, several of the extracts were more potent than pure DHB, indicating additional CYP3A 
inhibitors present in the supplements. This additional inhibitory activity may have been due to 
other furanocoumarins, including multimers, and/or other classes of CYP3A inhibitors. 
Trisorbagen, for example, was labeled to contain a standardized piperine composition, though it 
did not report actual quantities; piperine has been demonstrated previously to inhibit CYP3A 
activity in human liver microsomes (Ki ∼ 40 μM) [33] and may have contributed in the current 
study. Whether such inhibitory activity translates to the clinical setting remains to be determined. 
Further analysis of the supplements would provide additional insight by identifying the 
constituents responsible for the unexpected inhibitory potency. 
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Appendix A. Supplementary data 
 
Table S1. The mass of each capsule’s contents, in mg. AttentionLink was weighed in its entirety.  
 1 2 3 4 5 AVG RSD 
SciFit DHB 300 383.77 366.58 350.90 384.20 402.60 377.6 5.20 
Trisorbagen 350.69 345.86 353.62 313.65 358.61 344.5 5.18 
Xceler8 DHB 242.50 203.86 191.22 205.59 216.94 212.0 9.11 
AttentionLink 990.58 943.97 973.68 942.45 1011.71 972.5 3.08 
Finaflex Alpha 621.29 636.33 664.30 632.12 617.64 634.3 2.90 
Finaflex Andro 703.27 677.01 682.31 677.53 671.31 682.3 1.81 
 
Table S2.  Calculated content of bergamottin and DHB in supplements. DHB was not detected 
in any of the other supplements tested, and bergamottin was only detected in one other 
supplement (Xceler8 DHB). Due to matrix effects, the quantification of bergamottin in Xceler8 
DHB is not reported. DHB = 6',7'-dihydroxybergamottin. 
 μg/capsule SD  % weight of capsule SD 
      
DHB in SciFit DHB 300 (PDA)           
LOQ 0.22     
LOD 0.074     
       
Tablet 1 (383.77 mg) 66.68 0.64  0.01738 0.00017 
Tablet 2 (366.58 mg) 57.83 0.64  0.01577 0.00017 
Tablet 3 (350.9 mg) 64.06 0.64  0.01826 0.00018 
Tablet 4 (384.2 mg) 68.29 0.64  0.01778 0.00017 
Tablet 5 (402.6 mg) 70.69 0.64   0.01756 0.00016 
      
Bergamottin in SciFit DHB 300 (PDA)           
LOQ 2.0     
LOD 0.12     
       
Tablet 1 (383.77 mg) 11.70 0.23  0.003050 0.000061 
Tablet 2 (366.58 mg) 11.56 0.23  0.003152 0.000064 
Tablet 3 (350.9 mg) 11.86 0.23  0.003380 0.000066 
Tablet 4 (384.2 mg) 12.29 0.23  0.003200 0.000061 
Tablet 5 (402.6 mg) 13.24 0.23   0.003289 0.000058 
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